ArsenalBio

ArsenalBio Raises $325M Series C

Cell therapy company advancing programmable CAR-T and TIL therapies for cancer treatment with focus on solid tumors

Key Highlights

• Funding Amount: $325M Series C
• Valuation: Undisclosed
• Headquarters: South San Francisco, CA
• Founded: 2019
• Employees: 150-250
• Total Raised: $465M

About the Funding Round

ArsenalBio has successfully closed $325M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

• T. Rowe Price
• ARCH Venture Partners
• Andreessen Horowitz

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help ArsenalBio achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. ArsenalBio's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2019 and headquartered in South San Francisco, CA, ArsenalBio has established itself as an innovative player in the biotech space. With 150-250 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, ArsenalBio plans to:

• Accelerate product development and innovation
• Expand into new markets and geographies
• Grow the team across engineering, sales, and operations
• Strengthen partnerships with key industry players
• Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in ArsenalBio's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about ArsenalBio, visit their website or contact their press office.